Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis.

ABSTRACT:

Background

Mechanistic biosimulation can be used in drug development to form testable hypotheses, develop predictions of efficacy before clinical trial results are available, and elucidate clinical response to therapy. However, there is a lack of tools to simultaneously (1) calibrate the prevalence of mechanistically distinct, large sets of virtual patients so their simulated responses statistically match phenotypic variability reported in published clinical trial outcomes, and (2) explore alternate hypotheses of those prevalence weightings to reflect underlying uncertainty in population biology. Here, we report the development of an algorithm, MAPEL (Mechanistic Axes Population Ensemble Linkage), which utilizes a mechanistically-based weighting method to match clinical trial stati

SUBMITTER: Schmidt BJ 

PROVIDER: S-EPMC3717130 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature